1887
Volume 2011, Issue 1
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

To assess the efficacy and the tolerability of TAC (docetaxel, doxorubicin, and cyclophosphamide) protocol in early breast cancer patients with node positive in the adjuvant treatment 64 patients (median age 46 years) with early node positive breast cancer were studied from October 2003 to May 2009 according to certain inclusion criteria. They received TAC protocol chemotherapy; Disease free survival (DFS), Overall Survival (OS) and toxicity profile were assessed. All except one received six cycles of chemotherapy according to TAC protocol. Median follows-up was 60 months. Disease free (DFS) and Overall Survival (OS) were 77% and 87% respectively. The chemotherapy was well tolerated and the toxicity profile was better in comparison to previously published studies. It is concluded that TAC protocol in the adjuvant treatment of early breast cancer is effective and well-tolerated as evident by the toxicity profile provided the G-CSF is started as primary prophylaxis from the first cycle.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2011.1.14
2011-06-01
2019-11-19
Loading full text...

Full text loading...

References

  1. Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2008; 58::7196.
    [Google Scholar]
  2. Berry DA, Cirrincione C, Henderson IC. Estrogen receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006; 295::1658.
    [Google Scholar]
  3.   Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005; 365:9472:16871717.
    [Google Scholar]
  4. Eifel P, Axelson JA, Costa J. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer. J Natl Cancer Inst. 2001; 93::979. November 1 -3,2000.
    [Google Scholar]
  5. Cole BE, Gelber RD, Gelber S. Polychemotherapy for early breast cancer: An overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001; 358::277.
    [Google Scholar]
  6. Montero A, Fossella F, Hortobagyi G. Docetaxel for treatment of solid tumors: A systematic review of clinical data. Lancet Oncol. 2005; 6::229239.
    [Google Scholar]
  7.   Early Breast Cancer Tria lists' Collaborative Group. Poly chemotherapy for early breast cancer: An overview of the randomizedtrials. Lancet. 1998; 352::930942.
    [Google Scholar]
  8. Valero V, Holmes F, Walters RS. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline resistant metastatic breast cancer. J Clin Oncol. 1995; 13::28862894.
    [Google Scholar]
  9. Ravdin PM, Burris HA III, Cook G. Phase II trial of docetaxel in advance danthracycline-resistant or anthracenedione resistant breast cancer. J Clin Oncol. 1995; 13::28792885.
    [Google Scholar]
  10. Chan S, Fried richs K, Noel D. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999; 17::23412354.
    [Google Scholar]
  11. Schuller J, Czejka M, Kletzl H. Doxorubicin (DOX) and Taxotere (TXT) a pharmacokinetic (PK) study of the combination in advanced breast cancer. ProcAm Soc Clin Oncol. 1998; 17:205a, Abstract.
    [Google Scholar]
  12. Bellot R, Robert J, Dieras V. Taxotere (T) does not change the pharmacokinetic (PK) profile of doxorubicin (dox) and doxorubicinol (Dx-ol). Proc Am Soc Clin Oncol. 1998; 17:221a, Abstract.
    [Google Scholar]
  13. Gianni L, Munzone E, Capri G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995; 13::26882699.
    [Google Scholar]
  14. Gehl J, Boesgaard M, Paaske T. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996; 7::687693.
    [Google Scholar]
  15. Gianni L, Vigano L, Locatelli A. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997; 15::19061915.
    [Google Scholar]
  16. Nabholtz JM, Mackey JR, Smylie M. Phase II study of docetaxel, qdoxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol. 2001; 19::314321.
    [Google Scholar]
  17. Nabholtz JM, Falkson C, Campos D. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003; 21::968975, (Erratum, J Clin Oncol 2003; 21:2048).
    [Google Scholar]
  18. Mackey JR, Paterson A, Dirix LY. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FACas first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). ProcAm Soc Clin Oncol. 2002; 35a:, Abstract.
    [Google Scholar]
  19. Bontenbal M, Braun JJ, Creemers GJ. Phase III study comparing AT (Adriamycin, docetaxel) to FAC (fluorouracil, Adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur J Cancer Suppl. 2003; 1::S201.
    [Google Scholar]
  20. Nabholtz JM, Pienkowski T, Mackey J. Phase III trial comparing TAC (docetaxel, doxorubicin, and cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, and cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. ProcAm Soc Clin Oncol. 2002; 21:36a, Abstract.
    [Google Scholar]
  21. Martin M, Pienkowski T, Mackey J, et al., Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med. 2005; 352::23022313.
    [Google Scholar]
  22. Roche H, Fumoleau P, Spielmann M. Sequential adjuvant epirubicinbased and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol. 2006; 24::56645671.
    [Google Scholar]
  23. Bria E, Nistico C, Cuppone F. Benefit oftaxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer. 2006; 106:11:23372344.
    [Google Scholar]
  24. De Laurentiis M, Cancello G, D'Agostino D. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a metaanalysis of randomized trials. J Clin Oncol. 2008; 26:1:4453.
    [Google Scholar]
  25. Nabholtz JM, Mackey JR, Smylie M. Phase II study of docetaxel, doxorubicin,and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol. 2001; 19::314321.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2011.1.14
Loading
  • Article Type: Research Article
Keyword(s): adjuvant treatment , breast cancer , chemotherapy and TAC protocol
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error